- Email: [email protected]
Modulation of PIF-1-type helicases
cloning the size-selected gene products into an expression vector active in a heterologous host, using a novel cloning strategy expressing the peptides produced by the clones, and screening for clones that produce peptides that interact with an antibody or ligand of interest.
also controls the administration of drug following implantation. The adhesion of the coating and the rate at which the drug is delivered can be controlled by the selection of an appropriate bioabsorbable or biostable polymer and the ratio of drug to polymer in the solution.
Nucleic Acid Probes and Methods for Detecting Cryptococcus neoformans Barns et al. Amoco Corporation US 5464743; November 7, 1995 Nucleic acid probes for detecting yeasts capable of causing cryptococcosis, specifically Cryptococcus neoformans. The probes are complementary to the ribosomal ribonucleic acid sequences unique to Cryptococcus neofotmans and as such, can detect the rRNA, rDNA, or polymerase chain reaction amplification products of these genes.
Use of IM for the Treatment of Chronic Lymphocyte Leukemia and B-Cell Lymphomas Aderka et al. Yeda Research & Development Co. Ltd. US 546273 1; October 3 1, 1995 The use of interleukin-6 and/or salts, functional derivatives, muteins, or active fractions thereof in the treatment of chronic lymphocytic leukemia and B-cell lymphomas as well as such use together with the soluble interleukin-6 receptor to pharmaceutical compositions and a method of treating chronic lymphocytic leukemia or B-cell lymphomas.
Pharmaceuticals Local Delivery of Fibrinolysis-Enhancing Agents Dunn et al. University of Texas US 5468505; November 21, 1995 A method of preventing adhesions by topical administration of fibrinolysis-enhancing agents. The method uses a topically applied polymeric matrix for delivery of a fibrinolytic agent, preferably urokinase, or tPA. The matrix is extremely thin and is polymerized in situ to form a biodegradable polymeric matrix. The matrix provides controlled release of the agent over a period of time effective to prevent surgical adhesions and is biodegradable usually within the same time frame. Method for Introducing a Biological Substance into a Target Fitzpatrick-McElligott et al. E. I. Du Pont de Nemours & Co. US 5466587; November 14, 1995 A method for introducing a biological substance into a target which utilizes particles having a substantially pure carbonaceous surface to which is associated a biological substance wherein the particles are sufficiently small to penetrate the target without killing the target.
Fungi Isolation of Hepatitis B Surface Antigen from Transformed Yeast Cells Chi et al. Development Center for Biotechnology US 5462863; October 31, 1995 A method for recovering hepatitis B surface antigen protein from transformed yeast cells including a posthomogenizing step of an obtained suspension to obtain a lO-50% increase in yield of the hepatitis B surface antigen protein as calculated based on a yield achieved without performing the posthomogenizing step.
Applications Method for Quantifying BP1 in Body Fluids Carroll et al. Xoma Corporation US 5466580; November 14, 1995 A method for quantifying the presence of extracellular BP1 in body fluids including blood in a subject which comprises conducting a BP1 immunoassay on plasma obtained from the subject.
Processes and Compositions for the Isolation of Human Relaxin Henner et al. Genentech, Inc. US 5464756: November 7, 1995 A process for cleaving a polypeptide into at least two polypeptide components comprising treating a reduced, free cysteine form of the polypeptide with a cleaving agent under conditions for cleaving the polypeptide at a desired junction between the polypeptide cleavage products.
Modulation of PIF-l-Type Helicases Schulz et al. Fred Hutchison Cancer Research Center US 5466576; November 14. 1995 Method for affecting viability of a eucaryotic cell by contacting the cell with a modulator of the activity of a PIF-l-type helicase in the cell. Such contacting specifically increases or decreases the specific activity of the helicase in the cell.
Intravascular Stent and Method Berg et al. Medtronic, Inc. US 5464650; November 7, 1995 A method for making an intravascular stent by applying to the body of a stent a solution which includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the solvent and then evaporating the solvent. The inclusion of a polymer in intimate contact with a drug on the stent allows the drug to be retained on the stent during expansion of the stent and
High-Speed Flow Cytometric Separation of Viable Cells Buckie et al. System& Inc. US 5466572; November 14, 1995 Hematopoietic cell populations are separated to provide cell sets and subsets as viable cells with high purity and high yields based on the number of original cells present in the mixture. High-speed flow cytometry is employed using light characteristics of the cells to separate the cells where high-flow speeds are used to reduce the sorting time.
Enzyme Microb. Technol.,
1997, vol. 20, January
77
also controls the administration of drug following implantation. The adhesion of the coating and the rate at which the drug is delivered can be controlled by the selection of an appropriate bioabsorbable or biostable polymer and the ratio of drug to polymer in the solution.
Nucleic Acid Probes and Methods for Detecting Cryptococcus neoformans Barns et al. Amoco Corporation US 5464743; November 7, 1995 Nucleic acid probes for detecting yeasts capable of causing cryptococcosis, specifically Cryptococcus neoformans. The probes are complementary to the ribosomal ribonucleic acid sequences unique to Cryptococcus neofotmans and as such, can detect the rRNA, rDNA, or polymerase chain reaction amplification products of these genes.
Use of IM for the Treatment of Chronic Lymphocyte Leukemia and B-Cell Lymphomas Aderka et al. Yeda Research & Development Co. Ltd. US 546273 1; October 3 1, 1995 The use of interleukin-6 and/or salts, functional derivatives, muteins, or active fractions thereof in the treatment of chronic lymphocytic leukemia and B-cell lymphomas as well as such use together with the soluble interleukin-6 receptor to pharmaceutical compositions and a method of treating chronic lymphocytic leukemia or B-cell lymphomas.
Pharmaceuticals Local Delivery of Fibrinolysis-Enhancing Agents Dunn et al. University of Texas US 5468505; November 21, 1995 A method of preventing adhesions by topical administration of fibrinolysis-enhancing agents. The method uses a topically applied polymeric matrix for delivery of a fibrinolytic agent, preferably urokinase, or tPA. The matrix is extremely thin and is polymerized in situ to form a biodegradable polymeric matrix. The matrix provides controlled release of the agent over a period of time effective to prevent surgical adhesions and is biodegradable usually within the same time frame. Method for Introducing a Biological Substance into a Target Fitzpatrick-McElligott et al. E. I. Du Pont de Nemours & Co. US 5466587; November 14, 1995 A method for introducing a biological substance into a target which utilizes particles having a substantially pure carbonaceous surface to which is associated a biological substance wherein the particles are sufficiently small to penetrate the target without killing the target.
Fungi Isolation of Hepatitis B Surface Antigen from Transformed Yeast Cells Chi et al. Development Center for Biotechnology US 5462863; October 31, 1995 A method for recovering hepatitis B surface antigen protein from transformed yeast cells including a posthomogenizing step of an obtained suspension to obtain a lO-50% increase in yield of the hepatitis B surface antigen protein as calculated based on a yield achieved without performing the posthomogenizing step.
Applications Method for Quantifying BP1 in Body Fluids Carroll et al. Xoma Corporation US 5466580; November 14, 1995 A method for quantifying the presence of extracellular BP1 in body fluids including blood in a subject which comprises conducting a BP1 immunoassay on plasma obtained from the subject.
Processes and Compositions for the Isolation of Human Relaxin Henner et al. Genentech, Inc. US 5464756: November 7, 1995 A process for cleaving a polypeptide into at least two polypeptide components comprising treating a reduced, free cysteine form of the polypeptide with a cleaving agent under conditions for cleaving the polypeptide at a desired junction between the polypeptide cleavage products.
Modulation of PIF-l-Type Helicases Schulz et al. Fred Hutchison Cancer Research Center US 5466576; November 14. 1995 Method for affecting viability of a eucaryotic cell by contacting the cell with a modulator of the activity of a PIF-l-type helicase in the cell. Such contacting specifically increases or decreases the specific activity of the helicase in the cell.
Intravascular Stent and Method Berg et al. Medtronic, Inc. US 5464650; November 7, 1995 A method for making an intravascular stent by applying to the body of a stent a solution which includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the solvent and then evaporating the solvent. The inclusion of a polymer in intimate contact with a drug on the stent allows the drug to be retained on the stent during expansion of the stent and
High-Speed Flow Cytometric Separation of Viable Cells Buckie et al. System& Inc. US 5466572; November 14, 1995 Hematopoietic cell populations are separated to provide cell sets and subsets as viable cells with high purity and high yields based on the number of original cells present in the mixture. High-speed flow cytometry is employed using light characteristics of the cells to separate the cells where high-flow speeds are used to reduce the sorting time.
Enzyme Microb. Technol.,
1997, vol. 20, January
77